Assay

Financial-condition grades for SEC filers

Company Report · as of Oct 9, 2026


HomeCompaniesSectorsCalendarLast night

PMV Pharmaceuticals, Inc.PMVP · healthcare
GradeNonecomputable_factors_below_threshold: 6 of 14 inputs computable; 7 are required
Reliability0.83 AUCfailure model, filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate1.07% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025
Size band$12.5M to $120M assetstotal assets $116.6M[1]
Warningsshort runway, thin datanot computable: degenerate inputs, fortress balance sheet
Inputs computable6 of 14
Graded fromfilings received through Mar 6, 2026217 days before the rescan; every figure keyed to the SEC receipt date
Last close$1.492026-10-08; market equity $79.7M; iex feed
Price used in gradeNone
Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history
$1$1.5NovDecJanFebMarAprMayJunJulAugSepOct$1.49
ABCDE20132014201520162017201820192020202120222023202420252026

Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date.

Open this report as it stood on

Letter setLetterPercentileBand
Jan 21, 2012nonen/a
Mar 21, 2021nonen/aQ3
Mar 21, 2026nonen/aQ2

Each date opens the report as it stood on that rescan.

Business, in the company's words. Opening of Item 1 of the 10-K received Mar 6, 2026; the document on sec.gov.

We are a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53 is a well-defined tumor suppressor protein known as the “guardian of the genome,” and normal, or wild-type, p53 has the ability to eliminate cancer cells. However, mutant p53 proteins can be misfolded and lose their wild-type tumor suppressing function. These p53 mutations are found in approximately half of all cancers. The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979.

Warnings [top]

Short runway. cash runway is 2.1 months[2]
Thin data. 6 of 14 grade factors are computable; minimum is 7

7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.

The Fourteen Inputs [top]

Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.

InputPercentile, 0 to 100ValueSourcePeer medianPercentilePeersPeriod end
Profitability, sleeve percentile 72.7
Gross profitabilitynot computable32.2%
one or more required annual facts are missing
Return on invested capitalnot computable9.3%
one or more required annual facts are missing
Accruals ratio(2.7%)[1,3-5](6.6%)72.78112025-12-31
Gross margin stability, five yearsnot computable2.8 pts
five annual gross margins are required; found 0
Solvency, sleeve percentile 48.2
Twelve-month failure probability0.44%0.07%81.82482026-06-30
Altman Z double-prime(2.34)[1,6-11](0.31)46.57562025-12-31
Net debt to EBITDAnot computable1.82x
one or more required annual facts are missing
Interest coveragenot computable(4.51x)
one or more required annual facts are missing
Current ratio10.09x[6-7]2.96x16.28392025-12-31
Growth and financing, sleeve percentile 62.1
Revenue growth, three-year compoundnot computable10.0%
four annual observations are required; found 0
Free cash flow growth, three-year compoundnot computable10.9%
current FCF must be positive and base FCF must exceed $100,000
Reinvestment ratenot computable37.1%
NOPAT must exceed $100,000
Asset growth, three years(24.5%)[1,5,12-13]2.1%88.27042025-12-31
Net share issuance, one year2.7%[14-15]2.5%36.06342026-03-03

Gross profitability. Revenue less cost of goods sold, over total assets.

Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.

Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.

Twelve-month failure probability. CHS model; lower is stronger.

Net debt to EBITDA. Lower is stronger.

Net share issuance, one year. Split-adjusted; lower is stronger.

Among 371 Peers [top]

What the Price Implies [top]

Market measures at the 2026-10-08 close. None enters the grade. Percentile among graded peers with the same measure.

MeasureValuePeer medianPercentileReading
Twelve-month price change, skipping the latest month(13.6%)8.0%36hotter than 36 of 100 peers
Distance from 52-week high(17.2%)(31.4%)69closer to its high than 69 of 100 peers
EBIT to enterprise valuenot computable(1.5%)required accounting or market input is missing
Free cash flow yield(92.4%)(1.0%)6pricier than 94 of 100 peers
Book value to price0.900.2884pricier than 16 of 100 peers
Sales to pricenot computable0.31required accounting or market input is missing
Composite equity issuance, five years17.7%20.3%48more equity-funded than 48 of 100 peers
Relative strength against the sector, log excess return(0.36)(0.14)36ahead of 36 of 100 peers

Inputs: market equity $79.7M; EBIT -$86.2M; free cash flow -$73.6M; book equity $71.5M; cash $12.5M[16].

Diagnostics [top]

Diagnostics do not feed the grade.

Piotroski F-score: None of 9, period end 2025-12-31
Return on assets above zero(40.6%)✗ fail[3,5]
Operating cash flow above zero-$73.6M✗ fail[4]
Return on assets improved(17.4 pts)✗ fail[3,5,12,17]
Operating cash flow exceeds net income$4.2M✓ pass[3-4]
Long-term leverage felln/a[1,5,12]
Current ratio improved(213.0 pts)✗ fail[6-7,18-19]
No new shares issued2.7%✗ fail[14-15]
Gross margin improvedn/a
Asset turnover improvedn/a[5,12]
Cash, filings, liquidity
Cash and equivalents$12.5M[2]
Operating cash flow, four quarters-$71.3M[2,4,20-23]
Months of runway2.1
Late filings, two years0
NT 10-K or NT 10-Q
Days since last periodic filing56
10-Q received Aug 14, 2026
Median daily dollar volume$479,351
63 sessions
Days since newest grade input217

Downloads [top]

Sources [top]

Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.

#ConceptXBRL tagValuePeriod endReceivedFormLinks
1assetsus-gaap:Assets$116.6M2025-12-312026-03-0610-Kfiling · viewer · series
2cashus-gaap:CashAndCashEquivalentsAtCarryingValue$12.5M2026-06-302026-08-1410-Qfiling · viewer · series
3net incomeus-gaap:NetIncomeLoss-$77.7M2025-12-312026-03-0610-Kfiling · viewer · series
4operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$73.6M2025-12-312026-03-0610-Kfiling · viewer · series
5assetsus-gaap:Assets$191.3M2024-12-312026-03-0610-Kfiling · viewer · series
6current assetsus-gaap:AssetsCurrent$115.2M2025-12-312026-03-0610-Kfiling · viewer · series
7current liabilitiesus-gaap:LiabilitiesCurrent$11.4M2025-12-312026-03-0610-Kfiling · viewer · series
8retained earningsus-gaap:RetainedEarningsAccumulatedDeficit-$446.5M2025-12-312026-03-0610-Kfiling · viewer · series
9operating incomeus-gaap:OperatingIncomeLoss-$86.2M2025-12-312026-03-0610-Kfiling · viewer · series
10book equityus-gaap:StockholdersEquity$104.7M2025-12-312026-03-0610-Kfiling · viewer · series
11liabilitiesus-gaap:Liabilities$11.8M2025-12-312026-03-0610-Kfiling · viewer · series
12assetsus-gaap:Assets$252.2M2023-12-312025-03-0310-Kfiling · viewer · series
13assetsus-gaap:Assets$270.3M2022-12-312024-02-2910-Kfiling · viewer · series
14shares outstandingdei:EntityCommonStockSharesOutstanding53,329,3922026-03-032026-03-0610-Kfiling · viewer · series
15shares outstandingdei:EntityCommonStockSharesOutstanding51,933,6042025-03-032025-03-0310-Kfiling · viewer · series
16shares outstandingdei:EntityCommonStockSharesOutstanding53,458,0582026-08-142026-08-1410-Qfiling · viewer · series
17net incomeus-gaap:NetIncomeLoss-$58.7M2024-12-312026-03-0610-Kfiling · viewer · series
18current assetsus-gaap:AssetsCurrent$175.7M2024-12-312026-03-0610-Kfiling · viewer · series
19current liabilitiesus-gaap:LiabilitiesCurrent$14.4M2024-12-312026-03-0610-Kfiling · viewer · series
20operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$34.3M2026-06-302026-08-1410-Qfiling · viewer · series
21operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$19.7M2026-03-312026-05-1210-Qfiling · viewer · series
22operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$56.4M2025-09-302025-11-1210-Qfiling · viewer · series
23operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$36.6M2025-06-302026-08-1410-Qfiling · viewer · series

Limitations [top]

Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.

Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.

Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.

Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.

Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.